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Abstract
Background: In their article on “Evidence-based de-implementation for contradicted, unproven, and aspiring
healthcare practices,” Prasad and Ioannidis (IS 9:1, 2014) referred to extra-scientific “entrenched practices and other
biases” that hinder evidence-based de-implementation.
Discussion: Using the case example of the de-implementation of radical mastectomy, we disaggregated
“entrenched practices and other biases” and analyzed the historical, economic, professional, and social forces that
presented resistance to de-implementation. We found that these extra-scientific factors operated to sustain a
commitment to radical mastectomy, even after the evidence slated the procedure for de-implementation, because
the factors holding radical mastectomy in place were beyond the control of individual clinicians.
Summary: We propose to expand de-implementation theory through the inclusion of extra-scientific factors. If the
outcome to which we aim is appropriate and timely de-implementation, social scientific analysis will illuminate the
context within which the healthcare practitioner practices and, in doing so, facilitate de-implementation by pointing
to avenues that lead to systems change. The implications of our analysis lead us to contend that intervening in the
broader context in which clinicians work—the social, political, and economic realms—rather than focusing on
healthcare professionals’ behavior, may indeed be a fruitful approach to effect change.
Keywords: De-implementation, Social science, Evidence-based medicine

Background
In a perfect world, all medical decisions would be based
on evidence. While a lofty ideal to which most clinicians
aspire, the context of medical practice makes that goal
difficult to realize. On the one hand, there are tensions
between clinical scientists and clinical practitioners,
problems in the translation of research findings, and
difficulties in the timing and sequencing of developing,
assessing, adopting, and abandoning clinical practice
[1-6]. On the other hand, there are conflicts within
science, “evidence wars” [7] that weaken the power and
influence of the evidence on healthcare practices, and
much work that can be characterized as cleaning up the
evidence base so that it is strong and pure enough to
maximize impact (AGREE Project, Cochrane Collaboration,
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EQUATOR Network, GRADE Working Group). Narrowing the gap between research and practice is not simply a
matter of convincing knowledgeable and conscientious
practitioners to do the right thing, but rather acknowledging that clinicians’ practice patterns are located within a
social structural context so that even the strongest
evidence’s influence is mitigated by the conditions of the
context in which health care is practiced.
In their article on “Evidence-based de-implementation
for contradicted, unproven, and aspiring healthcare
practices,” Prasad and Ioannidis call these factors
“entrenched practices and other biases” [7]. We propose
to disaggregate “entrenched practices and other biases.”
Following the lead of Prasad and Ioannidis [7], we delineate the extra-medical influences of historical, economic,
political, and social contexts that should be considered
in de-implementation and illustrate using the case example of the de-implementation of radical mastectomy.

© 2015 Montini and Graham; licensee BioMed Central. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public
Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this
article, unless otherwise stated.
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Discussion
Historical context

Some drugs, devices, and procedures have a long and deep
practice history. They are entrenched in organizational
infrastructure, and that inertia makes de-implementation
of a routinized procedure particularly difficult. The case of
radical mastectomy illustrates historical entrenchment.
Radical mastectomy was developed as a treatment for
breast disease at the end of the 1800s, when women presented with tumors that were reported to be up to 5 in. in
diameter [8,9] that hemorrhaged, were infected by fungus,
emitted exhausting discharges, caused much pain, and metastasized [10]. Halsted developed his radical technique—
excision of the breast, pectoral (chest) muscles, axillary
lymph nodes, and associated skin and subcutaneous
tissue—in response to these conditions.
Prior to the late 19th century, cancer was believed to
be a blood disorder, not amenable to surgery [11]. That
view gave way to the theory of cancer as a local disease.
Physicians believed that once the breast succumbed to
the disease, it was diseased in toto [12], making it necessary to remove the complete breast. Next, they theorized
that breast cancer spread via the axilla, so surgeons
began removing the axillary nodes, whether or not they
evidenced disease [13]. Acceptance of the theory of local
disease with centrifugal spread encouraged surgeons to
operate early, without waiting for the traditional sign of
ulceration of the tumor to make the diagnosis of cancer.
In line with the theory of breast cancer as a local
disease that spread centrifugally, Halsted [9] and Meyer
[14] contended that cancer spread from the breast and
axilla to the pectoral muscles, and therefore, they too
should be removed. Halsted [9] also believed that cancer
could be spread by cutting through diseased tissues,
either because cancer cells were liberated or because a
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contaminated scalpel would infect new sites. This led to
the technique of cutting a wide margin of healthy tissue
along with the diseased portion of the breast and removing the entire breast and all associated tissue in one
piece at once, akin to amputating a limb.
Halsted’s version of mastectomy was distinguished
from that of his colleagues by his insistence on the routine performance of the procedure for the removal of
the breast exactly as he had defined it. The glands and
tissues specified by Halsted were no longer to be removed or not removed at the discretion of the individual
surgeon determining their approach on a case-by-case
basis; they were to be removed by him on a regular
basis. The Halsted approach signaled the standardization
of surgical treatment for breast cancer. Radical mastectomy became the unvarying response to every set of
symptoms and every medical history ([15]: page 64), and
until 1968, the number of radical mastectomies in the
USA increased each year.
As early as 1941 in Scotland, McWhirter began treating his patients with simple mastectomy and radiation
therapy [16,17]. Influenced by McWhirter, an American
surgeon, George Crile Jr., began experimenting with
lesser surgery and radiation treatment. Crile published
his first clinical report in 1961 in the Annals of Surgery
[18]. By 1965, there were four clinical reports or trials
published in the literature. Figure 1 shows the accumulation of the English language evidence base comparing
radical mastectomy to lesser procedures up to the 1990
US National Institutes of Health Consensus Development Conference on the treatment of early-stage breast
cancer [19]. Of note is that all of the trials except for
one, a 1972 clinical trial by Atkins et al. [20], found the
lesser surgery to be equal to or better than radical mastectomy or found that lesser surgery with adjuvant therapy
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and le May have highlighted the role of mindlines
(collectively reinforced, internalized, tacit guidelines) in
professional socialization [2], part of which includes clinicians’ beliefs and worldviews. What is often difficult to
tease apart, however, is whether worldviews/beliefs lead to
practice change or whether changes in practice catalyze
changes in worldviews to justify what they are proposing
(sometimes referred to as persuasive knowledge use). In
any case, paying attention to the history of the evolution
of clinicians’ worldviews and beliefs may provide important insight into the de-implementation process.

was superior to radical mastectomy. Results from the first
US clinical trial of postoperative radiation were published
in 1970. The number of clinical trials continued to grow,
and pooled analysis [21] and meta-analysis [22] confirmed
that lumpectomy (breast-conserving surgery to remove a
tumor (lump) in a breast and a small amount of normal
tissue around it [23]) plus radiation was just as effective as
mastectomy.
Radical mastectomy had a long reign as the treatment of
choice for breast cancer. However, its de-implementation
was eased because practitioners did not necessarily have
to completely abandon the procedure; they had something
they could do instead—modified radical mastectomy (surgery in which the breast, most or all of the lymph nodes
under the arm, and the lining over the chest muscles are
removed [23]). Figure 2 shows that as radical mastectomy
declined, modified radical mastectomy increased in the
USA. Therefore, de-implementation of radical mastectomy was facilitated by the development of radiotherapy
as adjuvant to lesser surgery and mammography to detect
breast cancer at an earlier stage when amenable to treatment with lesser surgery.
The historical view of breast cancer also reveals how
worldviews, theories championed by specialists, and individual clinicians’ beliefs about causal mechanisms of
disease mesh with practice decisions. When breast
cancer was thought to be a blood disorder, surgery was
not a viable option. When the paradigm shifted to view
breast cancer as a local disease, surgery became the
primary option and was used to support and justify the
Halsted approach. Others have also noted how clinicians’
beliefs about the body, pathophysiology, disease, and
treatments can support change (both adoption and deimplementation) and inhibit change when it runs counter to the current worldview [24]. More recently, Gabbay

Economic context

Some drugs, devices, and procedures have a complex
financial structure that can pit physicians, hospitals, the
pharmaceutical industry, and device manufacturers against
each other. If de-implementation has financial consequences for a sector that is powerful and profiting, economic entrenchment may be a barrier. The case of radical
mastectomy illustrates economic forces of resistance to
de-implementation.
In fee-for-service payment systems, the more a
provider does, the more profit is generated. Therefore,
the de-implementation of radical mastectomy in the
USA was up against the desire and need to maintain
well-established revenue streams. In 1986, Muñoz and
colleagues compared the cost of lumpectomy versus
mastectomy for stage I or stage II breast cancer at Long
Island Jewish Medical Center [25]. Hospital inpatient
and surgeon fees were higher for mastectomy compared
to lumpectomy, so one would assume that mastectomy
would be the favored option. However, after a lumpectomy, the hospital charged for outpatient radiotherapy,
and the services of a physician radiotherapist were also
reimbursed. Therefore, when considering who is profiting
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financially from the radical mastectomy slated for deimplementation, surgeons would lose financially, but
hospitals and radiologists would benefit from deimplementation [25].
In 2000, Palit et al. returned to the question of the
costs of breast-conserving surgery versus modified
radical mastectomy, in light of the evolving nature of
breast cancer treatment, especially the integration of
post-mastectomy reconstructive surgery into treatment
protocols [26]. They found that women who received
breast-conserving surgery had a shorter length of stay
and a lower cost of surgery than women who received
modified radical mastectomy (with or without reconstruction) [26]. However, the addition of radiotherapy
(typically 25 daily sessions) made the total cost of breastconserving surgery greater than that of modified radical
mastectomy alone and 16% greater than that of modified
radical mastectomy with reconstruction [26]. Palit et al.
found that breast-conserving surgery was underutilized
with respect to the number of women eligible and observed that the preference for modified radical mastectomy “appears to be guided primarily by physician
attitudes and confusion regarding standard eligibility
criteria” ([26]: page 444). Therefore, from an economic
perspective, it appears that modified radical mastectomy
would be difficult to sustain were it not for the positioning
of the surgeon, who performs the biopsy that confirms the
diagnosis and tumor staging, and thereby has the benefit
of a series of ongoing contacts with the woman patient
and therefore the opportunity to exert influence in the
choice of breast cancer treatment.
Furthermore, if a government payer or a private insurance company continues to reimburse a drug, device, or
procedure—even in the face of an evidence base that
indicates the need for de-implementation, most likely
there will be little incentive for de-implementation.
The context of politics and specialties

Some drugs, devices, and procedures have a wellestablished association with a particular practice specialty. Those seeking to promote the de-implementation
of a technology must consider who “owns” the drug, device, or procedure and assume that those clinicians
would want to keep what they have.
With respect to radical mastectomy, surgeons, who historically sought to distinguish themselves from generalists
who could only offer palliative care, were the specialists
who offered a treatment. After perfecting the procedure of
radical mastectomy, it became the standard treatment for
breast cancer. Paradoxically, this routinization of a procedure in order to reduce uncertainty about when to use
it resulted in “deskilling” or loss of clinical skills or judgment. Surgeons, in fact, were left with one approach to all
permutations of breast cancer. If the surgery failed to stop
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the disease, treatment failure was attributed to the surgery
coming too late or being too conservative [27]. Without
diagnostic procedures or alternative therapies, radical
mastectomy became entrenched as the only treatment for
breast cancer, and surgeons were the specialists who
treated it.
Radical mastectomy reached its heyday in the USA
during the 1950s, a time when radiation oncology was
beginning to take hold in Europe [15]. Advances in diagnostic radiology resulted in mammograms that provided
early detection, making it increasingly untenable for surgeons to continue to defend radical mastectomy as the
standard treatment when faced with patients who had
small tumors and a degree of malignancy that could now
be staged by ever more sophisticated pathology analysis.
Furthermore, by the late 1970s, surgeons were doing
biopsies on an outpatient basis, and women patients
were demanding a “two-step” procedure, i.e., separating
diagnostic biopsy from breast cancer treatment. Biopsy
allowed surgeons to hold their position as the point of
first contact in the definitive diagnosis of breast cancer,
but once through the gates and armed with a pathology
report, women patients with early non-metastasized cancer could seek the treatment options that involved other
specialties.
Social context

De-implementation does not necessarily occur within
the protected confines of research science and clinical
practice. Research and practice are situated in a broader
social context, and under some circumstances, the timing and sequencing of developing, assessing, adopting,
and abandoning drugs, devices, and procedures are
subject to outside social forces that affect health services.
The interest in de-implementing radical mastectomy
extended beyond biomedical researchers and clinicians.
At the same time that an evidence base was developing
in the USA, the social movements of the 1970s and
1980s catalyzed the women’s health movement. Movement participants challenged the authoritarian relations
within the practice of medicine, insisted on patient participation in medical decision-making, recognized patients’
psychological and social needs, and advocated that the patient’s experience be acknowledged in the doctor-patient
encounter. Lay activists encouraged women with breast
cancer to seek consultation from radiation and medical
oncologists and diagnostic biopsies from surgeons with a
reputation for considering the possibility of lesser surgery.
This sentiment was reflected in popular articles indexed
in the Readers’ Guide to Periodical Literature [28] that
discussed radical mastectomy. These articles were published in high-circulation journals, such as Readers’ Digest
(17,829,000), McCall’s (7,500,000), Good Housekeeping
(5,600,000), Newsweek (3,000,000), Consumer Reports
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(2,150,000), and Glamour (1,946,078) [29]. The intensity
of the viewpoints expressed is indicated by these select
titles of some articles: “Breast Cancer Debate: Mastectomy
study” [30], “Controversy over breast cancer: Radical
mastectomy” [31], “Right to choose: Mastectomy?” [32],
“Breast cancer: The retreat from radical surgery” [33], “I
said no to my doctors” [34], and “Breast Cancer: Death to
the Radical?” [35]. Furthermore, journalists often interviewed critics of radical mastectomy, such as surgeon
George Crile Jr. [36], noted coordinator of the national
randomized controlled trial of breast cancer treatments
Bernard Fisher [37], and coordinator of cross-national
trials Gianni Bonadonna [38].
The reporting on breast cancer in the popular literature indicates that consumers were aware that there was
controversy within medicine and that there were treatment alternatives to radical mastectomy. This awareness
may have led to some degree of patient pressure on surgeons. In a 1985 television interview on lumpectomy,
surgeon Susan Love claimed that, “This treatment option was not developed by doctors and surgeons looking
for a better way. It was women who said, ‘I refuse mastectomy. You better find another way to treat me’” [39].
De-implementation came at a time when there was a
convergence in clinicians’ and patients’ awareness of the
scientific evidence, patients expressing their preferences
for an alternative, and when there were other viable
treatments to offer instead of radical mastectomy.
While changing social forces strengthened women
patients’ role in de-implementing radical mastectomy,
recently researchers have noted an upward trend in the
rate of mastectomy. Katz et al. reported the relationship
between patients’ retrospective reporting of their involvement in breast cancer treatment decision-making
and the actual treatment they received [40]. Their survey
respondents reported that their concerns regarding the
recurrence of disease and the effects of radiation gave
rise to their preference for mastectomy over lumpectomy [40]. Gomez et al. found increasing rates of mastectomy in women diagnosed with ductal carcinoma in
situ (DCIS) who were white, younger than 50 years at
diagnosis, and living in the highest 20% of neighborhoods ranked by socioeconomic status [41]. The authors
contended that this group of women, who we would
expect to have high decision-making agency, most likely
preferred mastectomy because of negative attitudes toward radiotherapy, positive expectations regarding reconstruction, their understanding of their risk of recurrence,
and not wanting to undergo tamoxifen therapy for 5 years
post-lumpectomy (as recommended by a 2009 practice
guideline, tamoxifen therapy was not necessary for women
who were treated by mastectomy [42]). While we laud
these researchers for considering the patient’s role in treatment decision-making, we note that their methodology
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did not employ direct observations of the physicianpatient discussions of treatment courses (such as can be
found in Routine Complications by socio-linguist Candace
West [43]). Therefore, it is possible that surgeons influence their patients’ knowledge, attitudes, and beliefs
regarding the risk of recurrence of breast cancer, the possible effects of radiation, the utilization of tamoxifen, and
the promise of plastic surgery reconstruction. Given that a
modified radical mastectomy is a quicker and easier surgery than breast-conserving surgery that in the USA
commands higher surgeon fees [26], and is followed by
subsequent reconstructive surgery that upper socioeconomic status women would be able to afford, a consideration of financial and professional forces would suggest
that surgeons may be offering guidance that favors mastectomy over lumpectomy [26].
In Canada, where the costs of cancer surgery, radiation, and chemotherapy treatment are covered by
provincially funded healthcare plans and provided to all
citizens and landed immigrants, surgeons receive the
same fee for either breast-conserving surgery or mastectomy (modified radical or otherwise). Plastic surgeons
are the sole beneficiaries of a woman’s choice of reconstruction after a modified radical mastectomy. A recent
Canadian Institute for Health Information (CIHI) report
found that mastectomy rates exceeded 50% for women
who would have to travel 1.5 h or longer (each way) to
reach a center offering radiotherapy [44]. In this case, it
seems plausible to assume that women who live in rural
or sub-rural areas are avoiding travel to the approximately 25 daily radiation therapy visits following breastconserving surgery, rather than expressing a preference
for modified radical mastectomy surgery. Thus, the
distance a woman has to travel between her home and a
cancer center is a care delivery structural feature that
can be conceptualized as a social force that sustains the
use of modified radical mastectomy.
Summary

In sum, evidence did play a role in the case of
de-implementing radical mastectomy—but it was not
the star of the performance as would be hoped for from
an evidence-based medicine perspective.
We share Prasad and Ioannidis’ ideals regarding the
evolution of ever-better science to guide implementation
and de-implementation [7]. However, there are many
cases of factors other than science catalyzing and sustaining misguided implementation and of sound and
proven science failing to catalyze de-implementation
[27,45-47]. Even when the empirical evidence is strong,
scientific arenas may not necessarily be where the implementation/de-implementation decisions are made. Most
scientists eschew advocacy, preferring to “let the science
speak for itself” [48]. However, how can the science be
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heard, when there is a great deal of clatter from extrascientific historical, economic, professional, and social
forces in the practice arena?
Traditionally, the approach used to try to keep clinicians up to date has been continuing professional development or continuing medical education that relies on
pedagogical theory. This underlying assumption of this
approach is that if you educate people, they will be
enlightened and will change their actions in response to
the knowledge gained. In our experience, telling clinicians that the scientific evidence says what they are currently doing is no longer beneficial may not convince
them to de-implement because it may not have been the
scientific evidence that established the practice nor
sustained its utilization [2].
In the field of implementation science, the role of
psychological theories in understanding and predicting
clinician behavior is influential. This should not be surprising given that ultimately individual clinicians (and
their patients) make and follow through (or not) on
decisions about care. While we acknowledge that these
theories are helping to build our understanding of deimplementation, we believe that psychological theories
are best utilized in the interpersonal realms of how we
recruit, mobilize, involve, and retain clinicians on the
teams that work for de-implementation. For example,
Bowen and Graham have proposed an Engagement Paradigm in which scientists and clinicians collaborate to
create evidence that is pre-designed to be clinically relevant
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and utilizable [49]. Furthermore, Ong et al. demonstrated
that even when trying to precipitate behavior change
(a key issue for psychology), psychological theory may
offer little assistance [50]. Instead, they analyzed patient
practices and strategies in the broader social context to
explain why, for whom, and under what circumstances a
treatment works [50].
To advance the science of de-implementation, we
argue that the time is ripe for more in-depth analysis
and understanding of all of the factors operating to sustain commitment to medications, devices, procedures,
interventions, and tests that the evidence slates for deimplementation. There is a wealth of work from the disciplines of Science and technology studies, the History
and philosophy of science, the Sociology of health and
illness, and Medical Anthropology that addresses issues
of de-implementation in medicine and beyond. Table 1
delineates these disciplines, what they study, issues commonly addressed, methodological approaches typically
taken, and a sample publication for each.
There is much to be learned from applying social science approaches to study both resistance to de-implementation (e.g., radical mastectomy [27] and episiotomy [46]),
as well as appropriate and even rapid de-implementation
(e.g., halting the prescribing of rofecoxib and hormone
replacement therapy). Contrasting these findings with the
results from studies of rapid (both appropriate and
inappropriate) implementation (e.g., the rapid adoption
of experimental HIV drugs [45]) will advance our

Table 1 Disciplines that address de-implementation in medicine and the contexts of clinical practice
Discipline

What is studied

Medical anthropology The ways in which culture
and society are organized
around or influenced by
issues of health, health
care and related issues

Some issues of studies

Some approaches Sample publication

Folk medicine Ethnobotanical Field research
knowledge The culture limits Participant
observation
of biomedicine

Aggarwal NK, Nicasio AV, DeSilva R,
Boiler M, Lewis-Fernández R. “Barriers
to implementing the DSM-5 cultural
formulation interview: a qualitative
study.” Cult Med Psychiatry. 2013
Sep;37(3):505–33 [51]

Science and
technology studies

How social, political, and
Biotechnology Environmental
cultural values affect scientific sustainability Information
research and technological
technology
innovation

Science citation
index analysis
Historical analysis
Case comparisons

Obstfelder A, Engeseth KH, Wynn R.
“Characteristics of successfully
implemented telemedical applications.”
Implement Sci. 2007
Jul 27;2:25 [52]

Sociology of health
and illness

Medical organizations and
institutions, the production
of knowledge and selection
of methods, the actions and
interactions of healthcare
professionals, and the social
or cultural (rather than
clinical or bodily) effects of
medical practice

Experiences of patients
Health disparities Interactions
between sick people and
healthcare practitioners

Qualitative
interviewing
Demographic
analysis Survey
research

Timmermans S, Berg M. “The practice
of medical technology.” Sociol Health Ilnn.
2003;25:97–114 [53]

How the sciences originated,
how they were practiced,
how they were developed,
and how they were related to
their intellectual and social
contexts

Archival research
Textual analysis
Re-enactment of
experiments

Richard W,. Wertz and Dorothy C. Wertz.
Lying-In: A History of Childbirth in America.
1989, Yale University Press [54]

History and
Science, its nature and
philosophy of science fundamentals, its origins, and
its place in modern politics,
culture, and society
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understanding of de-implementation. Furthermore, as
we consider the extra-scientific forces that sustain
“entrenched practices and other biases” [7], we need to
search literature not indexed in typical medical databases such as PubMed, CINAHL, and EMBASE for
socio-historical analyses of de-implementation in health
and other fields (see for example, a provocative study of
CT scanners in radiology departments published in the
management literature [55]).
In sum, we contend that even when clinicians know
what practices are in accord with scientific evidence,
they often remain confined by a set of structural forces
beyond their control and are not able to make changes.
We propose to conceptualize de-implementation as systems change, leading to work for de-implementation at
the systems level. We suggest intervening in the broader
context in which clinicians work—the social, political,
and economic realms—to change systems rather than
trying to change individuals. We also argue that the time
is right to further develop our de-implementation theories to incorporate the social science that considers
historical, economic, professional, and social forces for
change.
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